Precision genomic testing to guide first-line LBCL treatment readiness
Official title: PRECISE LBCL: Precision Treatment Readiness Through Comprehensive Genomic Sequencing in 1st Line LBCL
Run by M.D. Anderson Cancer Center · NCT07829445 · Data updated 2026-11-12
Doctors will see if a tumor genomic test can help tailor first-line treatment for adults with LBCL by the start of the second cycle of standard therapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | September 29, 2026 |
| Main results expected | June 30, 2027 |
| Study ends | June 30, 2029 |
| Registry record updated | November 5, 2026 |
| Trial ID | NCT07829445 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with pathology-confirmed diffuse large B-cell lymphoma (not otherwise specified) or high-grade B-cell lymphoma, stage III/IV, eligible for full-dose standard anthracycline therapy, and with a biopsy suitable for BostonGene testing.
✕Probably not a fit
Patients whose tumor genomics are not yet informative or whose physician cannot access the test results by cycle 2 may not experience a benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study at UT MD Anderson Center evaluates whether the BostonGene Tumor Portrait Molecular Test results are available to treating physicians by the start of cycle 2 of full-dose anthracycline-based therapy in eligible diffuse large B-cell lymphoma patients. The trial uses standard-of-care treatment and examines how often genomic profiling information is ready to inform clinical decisions. Eligible participants are adults with stage III/IV disease and a biopsy suitable for testing, with no known CNS involvement and no concurrent therapeutic lymphoma trials planned. The primary objective is to determine the proportion of patients for whom test results are available to the physician by cycle 2. The study explores whether integrating comprehensive genomic information can support precision treatment readiness in frontline LBCL care.
Why it matters
Potential benefit: If successful, the approach could improve treatment planning by providing timely genomic insights to guide therapy choices.
How similar studies have gone: Previous work in precision oncology has shown that actionable genomic information can guide treatment in some lymphomas, but results vary by tumor type and testing platform.
Who can join: the full rules
Show full inclusion / exclusion criteria
Eligibility Criteria * Age ≥18y * Pathology-confirmed diffuse large B-cell lymphoma, not otherwise specified or high-grade B-cell lymphoma (HGBL) who are eligible for standard-of-care, full-dose 6 cycles of anthracycline-based treatment * Stage 3 or 4 disease by Lugano Criteria * Available biopsy sample for BostonGene Tumor Portrait™ test ( for sample preparation) Exclusion Criteria * Known central nervous system (CNS) disease (cases concerning for CNS involvement should be evaluated with MRI and lumbar puncture) * Any baseline characteristics that in the opinion of the treating physician would preclude patients from receiving standard-of-care anthracycline-based treatment * Participation (or planning to participate) in any therapeutic clinical trials for lymphoma during the planned treatment course. Note, patients who become eligible for other studies based on inadequate response, toxicity to therapy, or other reasons that arise after the initiation of standard therapy on this study are permitted to pursue those alternative trials as appropriate. Participation in other non-therapeutic and/or observational studies are permitted.
Where it's running
-
UT MD Anderson Cancer Center
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Dai Chihara, MD — UT MD Anderson Cancer Center
- Study coordinator: Dai Chihara, MD
- Email: DChihara@mdanderson.org
- Phone: (713) 563-5426
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Preventing heart problems in overweight/obese young sarcoma survivors with tirzepatide
This feasibility study tests whether tirzepatide can be safely given to overweight or obese young adults (18–39) who have completed doxorubicin for soft tissue or bone sarcoma to see if it’s feasible to use in the first year after therapy.
-
Predicting lymphedema risk in inflammatory breast cancer patients using preoperative body impedance analysis
This study tests whether a preoperative bioimpedance test can help identify IBC patients who are at risk for developing lymphedema.
-
Using Apple Vision Pro in image-guided procedures
This study tests whether the Apple Vision Pro can be used during CT-guided biopsy procedures to help with imaging and guidance.
-
Geniculate Artery Embolization for Knee Osteoarthritis in Cancer Patients
This study tests whether blocking knee blood vessels with a standard care procedure can help reduce pain and improve function in people with knee osteoarthritis who also have cancer.
-
Urothelial Carcinoma Biospecimen Collection and Data Study
This project tests collecting and storing tissue, blood, and imaging data from adults with urothelial carcinoma to support translational research.
-
Chatbot support for informed consent in research
A chatbot named CoCo is tested to see if it can help patients understand and feel satisfied with the consent process for research studies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.